Log In Sign up
The largest database of trusted experimental protocols
> Procedures > Laboratory Procedure > Urinalysis

Urinalysis

Urinalysis is the comprehensive examination of urine, a crucial diagnostic tool in modern medicine.
This process involves the physical, chemical, and microscopic analysis of urine samples to detect and monitor various health conditions, such as kidney disorders, urinary tract infections, and metabolic imbalances.
Urinalysis provides valuable insights into the body's overall well-being, helping clinicians make informed decisions about patient care.
By examining the color, clarity, pH, and specific gravity of urine, as well as the presence of various substances, urinalysis can help identify potential issues and guide appropriate treatment strategies.
This essential laboratory test is a vital component of comprehensive healthcare, contributing to the early detection and management of a wide range of medical conditions.

Most cited protocols related to «Urinalysis»

1
National Health and Nutrition Examination Survey III
NHANES III, which was conducted by the National Center for Health Statistics (NCHS) of the Centers for Disease Control and Prevention (CDC), was a 6-year survey during 1988–1994 designed to measure the health and nutrition status of the civilian, noninstitutionalized U.S. population ≥2 months of age. National population estimates and estimates for the three largest racial/ethnic subgroups in the U.S. population (non-Hispanic white, non-Hispanic black, and Mexican American) can be derived from each of the two individual 3-year phases (1988–1991 and 1992–1994) and from the full 6-year survey.
Sampling selection for NHANES III was based on a complex multistage area probability design. Children younger than 5 years, adults ≥60 years of age, non-Hispanic blacks, and Mexican Americans were oversampled to allow an adequate number of sample persons in these demographic groups from which population-based estimates could be derived. However, urine samples were not collected for children < 6 years of age. Data were collected through a household interview, and a standardized physical examination was conducted in a mobile examination center. Urine specimens for analyses, including those for measuring creatinine concentrations, were collected during this examination throughout the day. Pre-examination procedures depended on the age and health status of the individual. For example, persons > 12 years of age were asked to fast for 2–12 hr, depending on appointment times, and persons with known diabetes or < 12 years of age were asked to eat a normal diet before the examination. Sociodemographic information and medical histories of the survey participants and their families were collected during the household interviews. Details of the sample design have been published (Ezzati et al. 1992 ). The data set used in our analysis is a part of the public release data set for NHANES III (NCHS 2004a ).
Barr D.B., Wilder L.C., Caudill S.P., Gonzalez A.J., Needham L.L, & Pirkle J.L. (2004). Urinary Creatinine Concentrations in the U.S. Population: Implications for Urinary Biologic Monitoring Measurements. Environmental Health Perspectives, 113(2), 192-200.
Full text: Click here
Publication 2004
Adult Age Groups Child Creatinine Diabetes Mellitus Diet Hispanics Households Mexican Americans Negroes Physical Examination Population Group Urinalysis Urine Youth
2
Korean National Health Insurance Cohort
The data from the Korean National Health Insurance Service-Health Screening Cohort was used [8 (link)]. The Korean National Health Insurance Service (NHIS) chooses about 10% of random samples (n=about 515,000) directly from all people who had a health check-up from 2002 through 2003 year (n=about 5,150,000). The age and sex specific distributions of the cohort population is described in online [9 (link),10 ].
All of ≥40 years old Koreans and their families are requested to have a biannual health check without cost [11 (link)]. Because all Korean citizens are registered with a 13-digit resident registration number for lifelong, the thorough population statistics can be calculated in this study. All Koreans have to register in the NHIS. The 13-digit resident registration number has to be used in all Korean hospitals and clinics. Thus, the medical records was prevented to be overlapped, even in case of a patient moves from one place to another. In addition, the Korean Health Insurance Review and Assessment (HIRA) system managed all medical treatments in Korea. The causes and date of death diagnosed by medical doctors on the death certificate are legally announced to administrative entity.
This NHIS included health insurance claim codes (procedures and prescriptions), diagnostic codes using the International Classification of Disease-10 (ICD-10), death records, socioeconomic data and health check-up data (body mass index [BMI], drinking, smoking habit, blood pressure, urinalysis, hemoglobin, fasting glucose, lipid parameters, creatinine, and liver enzymes) for each participant over the period from 2002 to 2013 [10 ,11 (link)].
Kim S.Y., Min C., Oh D.J, & Choi H.G. (2019). Tobacco Smoking and Alcohol Consumption Are Related to Benign Parotid Tumor: A Nested Case-Control Study Using a National Health Screening Cohort. Clinical and Experimental Otorhinolaryngology, 12(4), 412-419.
Publication 2019
Blood Pressure Creatinine Diagnosis Enzymes Fingers Glucose Health Insurance Health Services, National Hemoglobin Index, Body Mass Koreans Lipids Liver National Health Insurance Patients Physicians Prescriptions Urinalysis
3
Validating Lupus Nephritis Identification
We employed inpatient and outpatient billing data from Medicaid patients at Brigham and Women's Hospital in Boston to identify lupus nephritis cases. We identified Medicaid patients seen 2000-2007 with > 2 claims for lupus (ICD9 710.0) and compared four separate ICD9-based strategies: 1: greater than 2 claims for any combination of acute or chronic glomerulonephritis (including lupus glomerulonephritis), acute or chronic renal failure, nephritis or nephrotic syndrome (including lupus nephrotic syndrome), renal failure or proteinuria (ICD-9 codes 580.-586. and 791.0), 2: greater than 2 claims for visit to a nephrologist, 3: either strategy 1 or strategy 2 and 4: both strategy 1 and strategy 2.
Independently and blinded to these results, two board-certified rheumatologists performed medical record reviews to validate lupus and lupus nephritis according to American College of Rheumatology Criteria for Systemic Lupus Erythematosus14 (link), 15 (link). To validate the presence of lupus nephritis, we employed the ACR criteria14 (link), 15 (link) referring to the presence of nephritis (persistent proteinuria > 0.5 gms/day, or > 3+ on urinalysis, or cellular casts), AND/OR biopsy-proven renal disease attributed to lupus and classified as Class-III-IV or V (focal or diffuse glomerulonephritis or membranous nephropathy) according to the World Health Organization classification16 (link) for subjects identified by each algorithm. We calculated the positive predictive value (PPV) for each strategy. PPV is calculated as the number with confirmed lupus nephritis divided by the total number subjects within that strategy.
Chibnik L.B., Massarotti E, & Costenbader K.H. (2010). Identification and Validation of Lupus Nephritis Cases Using Administrative Data. Lupus, 19(6), 741-743.
Publication 2010
Biopsy CD3EAP protein, human Cells Chronic Kidney Diseases Glomerulonephritis Inpatient Kidney Diseases Kidney Failure Lupus Erythematosus, Systemic Lupus Nephritis Lupus Vulgaris Membranous Glomerulonephritis Nephritis Nephrologists Nephrotic Syndrome Outpatients Patients Rheumatologist Urinalysis Vision
4
HIV-1 Infection Prevention Protocol
The primary effectiveness end point was HIV-1 infection, identified by seroconversion as determined with the use of a standard algorithm (Fig. S2 in the Supplementary Appendix). HIV-1 testing was performed monthly, and the study product was immediately withheld if any rapid HIV assay was positive, pending confirmation by means of an enzyme-linked immunosorbent assay and subsequent Western blotting. Participants who became infected with HIV-1 were offered enrollment in a seroconversion study and were referred for care. All end points were reviewed by an HIV-1 end-point adjudication committee, the members of which were unaware of the study-group assignments. Participants were followed for 8 weeks after the last visit at which empty containers and unused study product were returned, so that any delayed HIV-1 seroconversions could be detected.
Safety monitoring included monthly interviews and pregnancy testing, quarterly serum chemical testing and urine dipstick analysis of protein and glucose levels, and twice-yearly pelvic examinations. Adherence to the study product was assessed by means of a questionnaire administered by interview monthly; by monthly in-clinic counts of returned pills, empty pill bottles, or unused vaginal applicators; and by a quarterly audio computer-assisted self-interview (ACASI). Condom use and sexual practices were also assessed with an ACASI.
Marrazzo J.M., Ramjee G., Richardson B.A., Gomez K., Mgodi N., Nair G., Palanee T., Nakabiito C., van der Straten A., Noguchi L., Hendrix C.W., Dai J.Y., Ganesh S., Mkhize B., Taljaard M., Parikh U.M., Piper J., Mâsse B., Grossman C., Rooney J., Schwartz J.L., Watts H., Marzinke M.A., Hillier S.L., McGowan I.M, & Chirenje Z.M. (2015). Tenofovir-Based Preexposure Prophylaxis for HIV Infection among African Women. The New England journal of medicine, 372(6), 509-518.
Publication 2015
Biological Assay Condoms Contraceptives, Oral Enzyme-Linked Immunosorbent Assay Glucose HIV-1 HIV Infections HIV Seropositivity Pelvic Examination Proteins Safety Serum Urinalysis Vagina
5
Comprehensive Baseline Data Collection for Biobank

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2017
Antihypertensive Agents Blood Glucose Body Weight Cardiovascular Diseases Childbirth Complete Blood Count Coronary Angiography Diagnosis Drug Reaction, Adverse Eating Echocardiography Enzymes Ethanol High Blood Pressures Index, Body Mass Japanese Kidney Lipids Liver Function Tests Malignant Neoplasms Operative Surgical Procedures Pharmaceutical Preparations Pharmacotherapy Pressure, Diastolic Radiotherapy Systole Systolic Pressure Therapeutics Tumor Markers Urinalysis Woman

Most recents protocols related to «Urinalysis»

1
Characterization of Oral [14C]Vorasidenib Metabolism in Humans
Not available on PMC !

Example 8

Characterization of Absorption, Distribution, Metabolism, and Excretion of Oral [14C]Vorasidenib with Concomitant Intravenous Microdose Administration of [13C315N3]Vorasidenib in Humans

Metabolite profiling and identification of vorasidenib (AG-881) was performed in plasma, urine, and fecal samples collected from five healthy subjects after a single 50-mg (100 μCi) oral dose of [14C]AG-881 and concomitant intravenous microdose of [13C3 15N3]AG-881.

Plasma samples collected at selected time points from 0 through 336 hour postdose were pooled across subjects to generate 0—to 72 and 96-336-hour area under the concentration-time curve (AUC)-representative samples. Urine and feces samples were pooled by subject to generate individual urine and fecal pools. Plasma, urine, and feces samples were extracted, as appropriate, the extracts were profiled using high performance liquid chromatography (HPLC), and metabolites were identified by liquid chromatography-mass spectrometry (LC-MS and/or LC-MS/MS) analysis and by comparison of retention time with reference standards, when available.

Due to low radioactivity in samples, plasma metabolite profiling was performed by using accelerator mass spectrometry (AMS). In plasma, AG-881 was accounted for 66.24 and 29.47% of the total radioactivity in the pooled AUC0-72 h and AUC96-336 h plasma, respectively. The most abundant radioactive peak (P7; M458) represented 0.10 and 43.92% of total radioactivity for pooled AUC0-72 and AUC96-336 h plasma, respectively. All other radioactive peaks accounted for less than 6% of the total plasma radioactivity and were not identified.

The majority of the radioactivity recovered in feces was associated with unchanged AG-881 (55.5% of the dose), while no AG-881 was detected in urine. In comparison, metabolites in excreta accounted for approximately 18% of dose in feces and for approximately 4% of dose in urine. M515, M460-1, M499, M516/M460-2, and M472/M476 were the most abundant metabolites in feces, and each accounted for approximately 2 to 5% of the radioactive dose, while M266 was the most abundant metabolite identified in urine and accounted for a mean of 2.54% of the dose. The remaining radioactive components in urine and feces each accounted for <1% of the dose.

Overall, the data presented indicate [14C]AG-881 underwent moderate metabolism after a single oral dose of 50-mg (100 μCi) and was eliminated in humans via a combination of metabolism and excretion of unchanged parent. AG-881 metabolism involved the oxidation and conjugation with glutathione (GSH) by displacement of the chlorine at the chloropyridine moiety. Subsequent biotransformation of GSH intermediates resulted in elimination of both glutamic acid and glycine to form the cysteinyl conjugates (M515 and M499). The cysteinyl conjugates were further converted by a series of biotransformation reactions such as oxidation, S-dealkylation, S-methylation, S-oxidation, S-acetylation and N-dealkylation resulting in the formation multiple metabolites.

A summary of the metabolites observed is included in Table 2

TABLE 2
Retention
ComponentTimeMatrix
designation(Minutes)[M + H]+Type of BiotransformationPlasmaUrineFeces
Unidentified 17.00UnknownX
M2667.67a267N-dealkylationX
Unidentified 2UnknownX
Unidentified 3UnknownX
Unidentified 4UnknownX
Unidentified 5UnknownX
M51519.79b516OxidationX
M460-120.76b461OxidationX
M49921.22b500Dechloro-glutathioneXX
conjugation + hydrolysis
M51621.89b517Oxidative-deaminationX
M460-221.98b461OxidationX
M47222.76b473S-dealkylation + S-X
acetylation + reduction
M47622.76b477OxidationX
Unidentified 6UnknownX
M47423.63b475OxidationX
Unidentified 7UnknownX
M43025.88b431AG-881-oxidationX
M42630.62b427S-dealkylation + methylationX
M45831.03c459AG-69460X*
AG-88139.41b415AG-881XX
M42847.40b429S-dealkylation + oxidationX
Table 3 contains a summary of protonated molecular ions and characteristic product ions for AG-881 and identified metabolites

TABLE 3
RetentionCharacteristic
MetaboliteTimeProposed MetaboliteProduct Ions
designation(Minutes)[M + H]+Identification(m/z)Matrix
M266 7.88a267[Figure (not displayed)]
188, 187Urine
M51519.79b516[Figure (not displayed)]
429, 260, 164, 153Feces
M460-120.76b461[Figure (not displayed)]
379, 260, 164Feces
M49921.22b500[Figure (not displayed)]
437, 413, 260, 164, 137Urine Feces
M51621.89b517[Figure (not displayed)]
427, 260, 164, 153Feces
M460-221.98b461[Figure (not displayed)]
369, 260, 164, 139, 121, 93Feces
M47222.76b473[Figure (not displayed)]
429, 260, 179, 164, 153Feces
M47622.76b477[Figure (not displayed)]
395, 260, 164, 139, 119Feces
M47423.63b475[Figure (not displayed)]
260, 164, 68Feces
M43025.88b431[Figure (not displayed)]
260, 164, 155, 68Feces
M42630.62b427[Figure (not displayed)]
260, 164, 151Feces
M45831.03b459[Figure (not displayed)]
380, 311, 260, 183, 164, 130Plasma Fecesd
AG-88139.41b415[Figure (not displayed)]
319, 277, 260, 240, 164, 139, 119, 68Plasma Fecesd
M42847.40b429[Figure (not displayed)]
260, 164, 153Feces
Notes
aRetention time from analysis of a urine sample
bRetention time from analysis of a feces sample
cRetention time from analysis of a plasma sample
dM458 was only detected in feces by mass spectrometry, not by radioprofiling.
The proposed (theoretical) biotransformation pathways leading to the observed metabolites are shown in FIG. 1.

US11865079B2. Therapeutically active compounds and their methods of use (2024-01-09). Servier Pharmaceuticals LLC [US]. Inventors: Chandra Agarwal Prakash [US].
Full text: Click here
Patent 2024
Acetylation AG 30 Biotransformation Chlorine Dealkylation Deamination Elements, Radioactive Feces Glutamic Acid Glutathione Glycine Healthy Volunteers High-Performance Liquid Chromatographies Homo sapiens Hydrolysis Intravenous Infusion Ions Liquid Chromatography Mass Spectrometry Metabolism Methylation Parent Plasma Radioactivity Retention (Psychology) Tandem Mass Spectrometry Urinalysis Urine vorasidenib
2
Treating OTC Deficiency with mRNA
Not available on PMC !

Example 20

The spfash mutant mice were injected intravenously with a single dose of human OTC mRNA (either construct OTC-07 (SEQ ID NO:35) or OTC-12 (SEQ ID NO:40)) at either 0.5 mg/kg or 1.0 mg/kg, or a control mRNA encoding eGFP at a dose of 1 mg/kg, via tail vein injection. The mRNA was formulated in lipid nanoparticles (Compound II) for delivery into the mice. Urine was collected from mice 48 hours and 24 hours prior to mRNA injection for urinary orotic acid/creatinine analysis. All mice urine was collected for urinary orotic acid/creatinine levels 24 hours, 48 hours, 72 hours, 7 days, 14 days, or 21 days after dosing for each injected human OTC mRNA and for the injected eGFP control. FIG. 5 shows that administering a single dose of mRNA encoding human OTC (either construct OTC-07 or OTC-12) to spfash mice led to a substantial and sustained decrease in orotic acid levels for at least 21 days following the mRNA injection.

US11859215B2. Polynucleotides encoding ornithine transcarbamylase for the treatment of urea cycle disorders (2024-01-02). ModernaTX, Inc. [US]. Inventors: Zhijian Zhuo [US], Andrea Lea Frassetto [US], Paolo G. V. Martini [US], Vladimir Presnyak [US], Patrick Finn [US].
Full text: Click here
Patent 2024
A-A-1 antibiotic Animal Model Creatinine Homo sapiens Lipid Nanoparticles Mus Obstetric Delivery Orotic Acid RNA, Messenger Tail Urinalysis Urine Veins
3
Measuring Blood Pressure and Artery Flow in Pregnant Rats
As previously described [28 (link), 29 (link)], the blood pressure of conscious pregnant rats was measured using an automated computerized tail-cuff system after five consecutive training periods (Visitech BP2000, Visitech Systems, Inc., USA). The blood flow of the rat uterine artery was measured using a high-resolution ultrasound device (Esaote MyLab30 Gold, Esaote, Genova, Italy) to obtain two-dimensional images. Twenty-four-hour urine samples were collected on GD7.5 and GD19.5 for urine protein analysis.
Wang J., Zhang P., Liu M., Huang Z., Yang X., Ding Y., Liu J., Cheng X., Xu S., He M., Zhang F., Wang G., Li R, & Yang X. (2023). Alpha-2-macroglobulin is involved in the occurrence of early-onset pre-eclampsia via its negative impact on uterine spiral artery remodeling and placental angiogenesis. BMC Medicine, 21, 90.
Full text: Click here
Publication 2023
Arteries Blood Pressure Consciousness Gold Medical Devices Menstruation Disturbances Proteins Tail Ultrasonography Urinalysis Urine Uterine Circulation
4
Cost Analysis of sq-NSCLC Treatments
The costs of implementing each treatment were derived the perspective of Chinese healthcare system. All cost data were inflated to 2022, shown as 2022 US dollars (1 USD = 6.36 Chinese Yuan). We considered only direct medical costs, including drug costs, follow-up costs, monitoring costs, death costs, and costs for treatment of adverse reactions (AEs). Drug prices were obtained from the latest local public bid-winning price or public databases (41 –43 ). The prices of camrelizumab used in first-line or tislelizumab used in second-line were assumed to be the same as other indications of them which have entered the NRDL, considering the newly approved indication of sq-NSCLC would likely to be included in the list and the price is the same for all indications of the same drug in the NRDL. Prices for paclitaxel and gemcitabine were from the fifth batch of bids for centralized drug procurement of drugs in China in 2021 (41 –43 ). Because carboplatin, cisplatin, paclitaxel, docetaxel, and nedaplatin have multiple dosage forms in the Chinese market, we chose the commonly used dosage combination under the principle of minimizing cost. Follow-up costs and monitoring costs were derived from the healthcare documents (44 ), which included CT examination, blood test, urinalysis, and blood biochemical examination, as wells as diagnosis fee, injection fee, nursing fee, and bed fee. Costs of BSC and end-of-life were extracted from published literature. We considered only severe AEs (≥grade 3) with rates >5%. AE related treatment costs and durations of AE were extracted from published articles. All AEs were assumed to occur during the first cycle (45 (link)). Details are listed in Table 1.
Zhao M., Shao T., Chi Z, & Tang W. (2023). Effectiveness and cost-effectiveness analysis of 11 treatment paths, seven first-line and three second-line treatments for Chinese patients with advanced wild-type squamous non-small cell lung cancer: A sequential model. Frontiers in Public Health, 11, 1051484.
Full text: Click here
Publication 2023
4-benzamido-4'-isothiocyanostilbene-2,2'-disulfonate BLOOD camrelizumab Carboplatin Chinese Cisplatin Diagnosis Docetaxel Gemcitabine Hematologic Tests nedaplatin Non-Small Cell Lung Carcinoma Paclitaxel Pharmaceutical Preparations tislelizumab Urinalysis
5
Anti-dsDNA Antibody ELISA Protocol
Anti-dsDNA antibody titers were determined using ELISA as previously described (Choi et al., 2017 (link)). Briefly, ELISA plates were coated with methylated BSA (Sigma-Aldrich) followed by calf thymus DNA. Diluted sera were added to the plates and incubated overnight at 4°C. Anti-dsDNA antibodies were detected with goat anti-mouse IgG conjugated to HRP (Southern Biotechnology). Plates were developed with TMB Microwell peroxidase Substrate (SureBlue; KPL) according to the manufacturer’s directions and read at 450 nm using a microplate reader. Proteinuria was measured using Uristix urinalysis reagent strips (Siemens). Splenocyte preparations were made and stained for flow cytometry as described above.
Seth A., Yokokura Y., Choi J.Y., Shyer J.A., Vidyarthi A, & Craft J. (2023). AP-1–independent NFAT signaling maintains follicular T cell function in infection and autoimmunity. The Journal of Experimental Medicine, 220(5), e20211110.
Publication 2023
Anti-dsDNA antibody anti-IgG calf thymus DNA Enzyme-Linked Immunosorbent Assay Flow Cytometry Goat Mice, House Peroxidase Reagent Strips Serum Urinalysis

Top products related to «Urinalysis»

1
Multistix 10 sg by Siemens
Sourced in United States, Germany
Multistix 10 SG is a laboratory urinalysis test strip that can measure up to 10 different analytes in a urine sample, including glucose, protein, bilirubin, and pH. The test strips provide semi-quantitative results and are designed for use in clinical settings to assist in the diagnosis and monitoring of various health conditions.
2
Sas 9 by SAS Institute
Sourced in United States, Austria, Japan, Belgium, United Kingdom, Cameroon, China, Denmark, Canada, Israel, New Caledonia, Germany, Poland, India, France, Ireland, Australia
SAS 9.4 is an integrated software suite for advanced analytics, data management, and business intelligence. It provides a comprehensive platform for data analysis, modeling, and reporting. SAS 9.4 offers a wide range of capabilities, including data manipulation, statistical analysis, predictive modeling, and visual data exploration.
3
Sas version 9 by SAS Institute
Sourced in United States, Austria, Japan, Cameroon, Germany, United Kingdom, Canada, Belgium, Israel, Denmark, Australia, New Caledonia, France, Argentina, Sweden, Ireland, India
SAS version 9.4 is a statistical software package. It provides tools for data management, analysis, and reporting. The software is designed to help users extract insights from data and make informed decisions.
4
Urine protein test kit by Nanjing Jiancheng
Sourced in China
The Urine Protein Test Kit is a laboratory equipment designed to detect the presence and measure the concentration of protein in urine samples. It provides a simple and accurate way to assess kidney function and screen for potential kidney disorders.
5
Cobas 6000 by Roche
Sourced in Switzerland, Germany, United States, Japan, Denmark, Italy, France, United Kingdom, Belgium, Norway, China, Israel, Poland, Netherlands, Sweden
The Cobas 6000 is an automated clinical chemistry and immunoassay analyzer system designed for high-volume laboratory testing. It combines the features of two separate instruments, the Cobas c 501 module for clinical chemistry and the Cobas e 601 module for immunoassays, into a single integrated platform. The Cobas 6000 system is capable of performing a wide range of diagnostic tests, including biochemical, immunological, and specialty assays.
6
Au5800 by Beckman Coulter
Sourced in United States, Japan, Germany, United Kingdom, China, Italy, Canada
The AU5800 is a chemistry analyzer designed for high-throughput clinical laboratory testing. It features advanced optics and automation to provide reliable and efficient sample processing. The core function of the AU5800 is to perform a variety of clinical chemistry tests, including immunoassays, on patient samples.
7
Clinitek status analyzer by Siemens
Sourced in United States
The Clinitek Status Analyzer is a compact, automated urine chemistry analyzer designed to perform a variety of in-vitro diagnostic tests. The device is capable of analyzing urine samples and providing quantitative or semi-quantitative results for various analytes such as glucose, protein, and bilirubin. The Clinitek Status Analyzer is intended for professional use in clinical laboratory or point-of-care settings.
8
Combur 10 test by Roche
Sourced in Switzerland
The Combur 10 Test is a urine test strip manufactured by Roche. It is designed to detect the presence and concentration of various analytes in urine samples, including glucose, protein, blood, pH, and more.
9
Prism 8 by GraphPad
Sourced in United States, Austria, Canada, Belgium, United Kingdom, Germany, China, Japan, Poland, Israel, Switzerland, New Zealand, Australia, Spain, Sweden
Prism 8 is a data analysis and graphing software developed by GraphPad. It is designed for researchers to visualize, analyze, and present scientific data.
10
Clarus 600t by PerkinElmer
Sourced in United States, Finland
The Clarus 600T is a gas chromatograph (GC) system designed for precise analysis of complex samples. It features a robust thermal desorption system and highly sensitive detectors to enable accurate identification and quantification of a wide range of organic compounds.

More about "Urinalysis"

Urinalysis is a comprehensive examination of urine, a crucial diagnostic tool in modern medicine.
This process involves the physical, chemical, and microscopic analysis of urine samples to detect and monitor various health conditions, such as kidney disorders, urinary tract infections, and metabolic imbalances.
Urinalysis provides valuable insights into the body's overall well-being, helping clinicians make informed decisions about patient care.
By examining the color, clarity, pH, and specific gravity of urine, as well as the presence of various substances, urinalysis can help identify potential issues and guide appropriate treatment strategies.
This essential laboratory test is a vital component of comprehensive healthcare, contributing to the early detection and management of a wide range of medical conditions.
Urinalysis can be performed using a variety of tools and methods, including Multistix 10 SG, SAS 9.4, SAS version 9.4, Urine protein test kits, Cobas 6000, AU5800, Clinitek Status Analyzer, Combur 10 Test, Prism 8, and Clarus 600T.
These technologies and products offer advanced analysis capabilities, enabling healthcare professionals to accurately assess urine samples and make informed decisions about patient care.
The findings from urinalysis can also be used to monitor the effectiveness of treatment and track the progression or resolution of various medical conditions.
With the help of cutting-edge AI platforms like PubCompare.ai, researchers can optimize their urinalysis studies by identifying the most effective protocols and methods from literature, preprints, and patents, ensuring reproducibility and accuracy in their research.